Evidence map›Paper›PMID 41114526›Full record

ArticleAging cell2025

Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria.

Moritz Schroll, Yacine Amar, Peter Krüger, Klaus Neuhaus, Karima Djabali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Moritz SchrollEpigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine and Health, Munich Institute of Biomedical Engineering, Technical University of Munich, Garching, Germany.ORCID 0009-0002-4865-0187
Yacine AmarDepartment of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
Peter KrügerEpigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine and Health, Munich Institute of Biomedical Engineering, Technical University of Munich, Garching, Germany.ORCID 0000-0002-0461-0645
Klaus NeuhausCore Facility Microbiome, ZIEL-Institute for Food & Health, Technical University of Munich, Freising, Germany.ORCID 0000-0002-6020-2814
Karima DjabaliEpigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine and Health, Munich Institute of Biomedical Engineering, Technical University of Munich, Garching, Germany.ORCID 0000-0003-4067-4977

Funding

Progeria Research Foundation 2022-82
6 · The paper itself

Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is a fatal genetic disorder caused by progerin, a mutant lamin A variant that disrupts nuclear architecture and drives systemic cellular dysfunction. Gastrointestinal (GI) involvement in HGPS remains poorly understood, despite growing evidence of gut abnormalities and microbial dysbiosis in progeroid mouse models. Here, we provide the first comprehensive characterization of colonic pathology in Lmna

Indexed as

AzetidinesColonGastrointestinal MicrobiomeHomeostasisPiperidinesProgeriaPurinesPyrazolesPyridinesSulfonamidesAnimalsDibenzocycloheptenesDisease Models, AnimalMiceAzetidinesbaricitinibDibenzocyclohepteneslonafarnibPiperidinesPurinesPyrazolesPyridinesSulfonamidesBaricitinibHutchinson‐Gilford progeria syndrome; JAK–STATlonafarnibmicrobiome

Identifiers

PMID41114526
PMCPMC12686558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.